Revealing metastatic castration‐resistant prostate cancer master regulator through lncRNAs‐centered regulatory network

• Published in: Cancer medicine (Malden, MA) Vol. 12; no. 18; pp. 19279 - 19290
• Main Authors: Ferraz, Rafaella Sousa, Cavalcante, João Vitor Ferreira, Magalhães, Leandro, Ribeiro‐dos‐Santos, Ândrea, Dalmolin, Rodrigo Juliani Siqueira
• Format: Journal Article
• Language: English
• Published: Bognor Regis John Wiley & Sons, Inc 01.09.2023; John Wiley and Sons Inc; Wiley
• Subjects: Androgen receptors; Androgens; Cancer therapies; Castration; Datasets; Down-regulation; Genes; Lethality; long noncoding RNA; Lymphatic system; mCRPC; Metastases; Metastasis; Non-coding RNA; Patients; Prostate cancer; Proteins; Regulatory sequences; system biology; transcriptional network reconstruction; Tumors
• ISSN: 2045-7634; 2045-7634
• DOI: 10.1002/cam4.6481

Background Metastatic castration‐resistant prostate cancer (mCRPC) is an aggressive form of cancer unresponsive to androgen deprivation therapy (ADT) that spreads quickly to other organs. Despite reduced androgen levels after ADT, mCRPC development and lethality continues to be conducted by the androgen receptor (AR) axis. The maintenance of AR signaling in mCRPC is a result of AR alterations, androgen intratumoral production, and the action of regulatory elements, such as noncoding RNAs (ncRNAs). ncRNAs are key elements in cancer signaling, acting in tumor growth, metabolic reprogramming, and tumor progression. In prostate cancer (PCa), the ncRNAs have been reported to be associated with AR expression, PCa proliferation, and castration resistance. In this study, we aimed to reconstruct the lncRNA‐centered regulatory network of mCRPC and identify the lncRNAs which act as master regulators (MRs). Methods We used publicly available RNA‐sequencing to infer the regulatory network of lncRNAs in mCRPC. Five gene signatures were employed to conduct the master regulator analysis. Inferred MRs were then subjected to functional enrichment and symbolic regression modeling. The latter approach was applied to identify the lncRNAs with greater predictive capacity and potential as a biomarker in mCRPC. Results We identified 31 lncRNAs involved in cellular proliferation, tumor metabolism, and invasion‐metastasis cascade. SNHG18 and HELLPAR were the highlights of our results. SNHG18 was downregulated in mCRPC and enriched to metastasis signatures. It accurately distinguished both mCRPC and primary CRPC from normal tissue and was associated with epithelial–mesenchymal transition (EMT) and cell‐matrix adhesion pathways. HELLPAR consistently distinguished mCRPC from primary CRPC and normal tissue using only its expression. Conclusion Our results contribute to understanding the regulatory behavior of lncRNAs in mCRPC and indicate SNHG18 and HELLPAR as master regulators and potential new diagnostic targets in this tumor.